PCF invests $6.3M in 31 Young Investigator Awards, supports Creativity Awards, and hosts Home Run Challenge 2026 to raise awareness. The foundation has contributed to 15 FDA-approved therapies over its 30-year history.
New research shows genomic profiling can detect aggressive prostate cancer not identified at biopsy, while a separate study reveals PTGES3 as a potential therapeutic target for treatment-resistant disease.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06826924 |
7-Days Water-Only Fasting or Ketone Supplementation Trial in Prostate Cancer |
RECRUITING | NA |
| NCT06305598 |
Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer |
ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT06046040 |
TmPSMA-02 in mCRPC |
ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT05918263 |
Exercise for Tumor Suppressive Impact in Men With Prostate Cancer at High-Risk of Progression on Active Surveillance: The REMOVE Trial |
RECRUITING | NA |
| NCT05765500 |
RecoverPC: Relugolix vs GnRH Agonist in Quality of Life |
RECRUITING | PHASE2 |
| NCT05471414 |
Whole-Food Plant-Based Diet to Control Weight and MetaboInflammation in Overweight/Obese Men With Prostate Cancer |
ACTIVE_NOT_RECRUITING | NA |
| NCT05327465 |
Exercise to Enhance Cardiovascular Health Among Black Prostate Cancer Patients With Androgen Deprivation Therapy |
RECRUITING | NA |
| NCT05113537 |
Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer |
RECRUITING | PHASE1/PHASE2 |
| NCT04457232 |
Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology Validation |
ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT04090528 |
pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer |
ACTIVE_NOT_RECRUITING | PHASE2 |
